Transfection with CD40L induces tumoursuppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma

¹ University of Heidelberg, Germany

^* To whom correspondence should be addressed. E-mail: angela.maerten{at}med.uni-heidelberg.de.

Accepted 17 July 2007

	Abstract

Objective: Patients with adenocarcinoma of the pancreas have only limited promising therapy options. Therefore, immunotherapeutical approaches might be considered a promising therapy that has gained in importance over the last years. In this study, CD40L gene transfer was tested as potent immunotherapy.

Methods: The efficacy of CD40L gene transfer in initiating anti-Tumour immune response was investigated in pancreatic ductal adenocarcinoma orthotopic syngeneic mouse model and the role of dendritic cells was determined, as well.

Results: Significant slower Tumour growth rate and less metastasis were observed following administration of CD40L plasmid. Meanwhile, such an effect of the plasmid was not observed in immunodeficient mice. Tumours of treated mice were found to be infiltrated with T cells and dendritic cells. The later were mature and of myeloid origin. Tumour-infiltrating lymphocytes were Tumour-specific as shown in IFN- ELISPot assays. Using intravital microscopy it was possible to exhibit the significant induction of leukocytes sticking to the Tumour endothelium after CD40L treatment. By performing adoptive cell transfer experiments, it has revealed that Tumour-derived dendritic cells and CD8 cells from CD40L-treated donor mice either harbour anti-Tumour activity or induce it in the recipients. Distinctly, CD8 cells from donor-spleens were found to migrate directly into the recipients' Tumour.

Conclusions: The induction of anti-Tumour activity initiated after treating mice with CD40L plasmid was realised. Further investigations showed that this is mediated by mature myeloid dendritic cells which activate CD8 cells. Clinical trials investigating CD40L-based therapies should be extended.

Keywords: CD40L, immunotherapy, pancreatic adenocarcinoma

Relevant Article

Genetic adjuvant therapy for pancreatic cancer and other solid tumours

Kenneth Christopher Bagley
Gut 2008 57: 289-291. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				A. Marten, N. Zeiss, S. Serba, S. Mehrle, M. von Lilienfeld-Toal, and J. Schmidt Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma Mol. Cancer Ther., November 1, 2008; 7(11): 3624 - 3631. [Abstract] [Full Text] [PDF]

				K. C. Bagley Genetic adjuvant therapy for pancreatic cancer and other solid tumours Gut, March 1, 2008; 57(3): 289 - 291. [Full Text] [PDF]